m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02457)
Name
URMC-099
Synonyms
compound 1 [PMID 24044867]
    Click to Show/Hide
Status
Investigative
Structure
Formula
C27H27N5
InChI
1S/C27H27N5/c1-31-10-12-32(13-11-31)18-19-2-4-20(5-3-19)23-15-24-25(17-30-27(24)29-16-23)21-6-7-26-22(14-21)8-9-28-26/h2-9,14-17,28H,10-13,18H2,1H3,(H,29,30)
InChIKey
QKKIWEILHCXECO-UHFFFAOYSA-N
PubChem CID
54764565
TTD Drug ID
D07ADX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Death-associated protein kinase 3 (DAPK3)
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Death-associated protein kinase 3 (DAPK3) is a therapeutic target for URMC-099. The Protein virilizer homolog (VIRMA) has potential in affecting the response of URMC-099 through regulating the expression of Death-associated protein kinase 3 (DAPK3). [1], [2]
SRSF protein kinase 2 (SRPK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary SRSF protein kinase 2 (SRPK2) is a therapeutic target for URMC-099. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of URMC-099 through regulating the expression of SRSF protein kinase 2 (SRPK2). [3], [4]
References
Ref 1 VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification. Cancer Lett. 2021 Dec 1;522:142-154. doi: 10.1016/j.canlet.2021.08.027. Epub 2021 Sep 11.
Ref 2 Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. doi: 10.1007/s10637-015-0273-z. Epub 2015 Aug 14.
Ref 3 FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014 Dec;24(12):1403-19. doi: 10.1038/cr.2014.151. Epub 2014 Nov 21.
Ref 4 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. doi: 10.1042/0264-6021:3510095.